Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab

Seminars in Cancer Biology

Volumn 13, Issue 3, 2003, Pages 223-231

  Hirt, Carsten ^a   Schüler, Frank ^a   Dölken, Gottfried ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Anti CD20 antibody; Follicular lymphoma; Minimal residual disease (MRD); Quantitative real time PCR; Rituximab; t(14; 18) translocation

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TENIPOSIDE;

CANCER CHEMOTHERAPY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DRUG EFFICACY; EVALUATION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOTHERAPY; LYMPHOMA CELL; MINIMAL RESIDUAL DISEASE; MONITORING; POLYMERASE CHAIN REACTION; PROGNOSIS; REMISSION; REVIEW; STANDARDIZATION; STEM CELL TRANSPLANTATION;

EID: 0038054906     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(03)00017-8     Document Type: Review

References (87)

1. Gallagher C.J., Gregory W.M., Jones A.E., Stansfeld A.G., Richards M.A., Dhaliwal H.S.et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 4:1986;1470-1480.
2. Johnson P.W., Rohatiner A.Z., Whelan J.S., Price C.G., Love S., Lim J.et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13:1995;140-147.
3. Dölken G. Detection of minimal residual disease. Adv. Cancer Res. 82:2001;133-185.
4. Weiss L.M., Warnke R.A., Sklar J., Cleary M.L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med. 317:1987;1185-1189.
5. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 226:1984;1097-1099.
6. Cleary M.L., Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. U.S.A. 82:1985;7439-7443.
7. Lee M.S., Chang K.S., Cabanillas F., Freireich E.J., Trujillo J.M., Stass S.A. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science. 237:1987;175-178.
8. Yamada M., Hudson S., Tournay O., Bittenbender S., Shane S.S., Lange B.et al. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc. Natl. Acad. Sci. U.S.A. 86:1989;5123-5127.
9. Zwicky C.S., Maddocks A.B., Andersen N., Gribben J.G. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood. 88:1996;3314-3322.
10. Cave H., van der Werff ten Bosch, Suciu S., Guidal C., Waterkeyn C., Otten J.et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N. Engl. J. Med. 339:1998;591-598.
11. Freedman A.S., Neuberg D., Mauch P., Soiffer R.J., Anderson K.C., Fisher D.C.et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 94:1999;3325-3333.
12. Apostolidis J., Gupta R.K., Grenzelias D., Johnson P.W., Pappa V.I., Summers K.E.et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J. Clin. Oncol. 18:2000;527-536.
13. Finke J., Slanina J., Lange W., Dölken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J. Clin. Oncol. 11:1993;1668-1673.
14. Dölken G., Illerhaus G., Hirt C., Mertelsmann R. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J. Clin. Oncol. 14:1996;1333-1344.
15. Liu Y., Hernandez A.M., Shibata D., Cortopassi G.A. BCL2 translocation frequency rises with age in humans. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8910-8914.
16. Fukuhara S., Rowley J.D., Variakojis D., Golomb H.M. Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Res. 39:1979;3119-3128.
17. Graninger W.B., Seto M., Boutain B., Goldman P., Korsmeyer S.J. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J. Clin. Invest. 80:1987;1512-1515.
18. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
19. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
20. McDonnell T.J., Deane N., Platt F.M., Nunez G., Jaeger U., McKearn J.P.et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:1989;79-88.
21. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature. 349:1991;254-256.
22. Horsman D.E., Gascoyne R.D., Coupland R.W., Coldman A.J., Adomat S.A. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am. J. Clin. Pathol. 103:1995;472-478.
23. Albinger-Hegyi A., Hochreutener B., Abdou M.T., Hegyi I., Dours-Zimmermann M.T., Kurrer M.O.et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am. J. Pathol. 160:2002;823-832.
24. Tsujimoto Y., Gorham J., Cossman J., Jaffe E., Croce C.M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 229:1985;1390-1393.
25. Cleary M.L., Galili N., Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J. Exp. Med. 164:1986;315-320.
26. Tsujimoto Y., Bashir M.M., Givol I., Cossman J., Jaffe E., Croce C.M. DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bcl-2 gene. Proc. Natl. Acad. Sci. U.S.A. 84:1987;1329-1331.
27. Akasaka T., Akasaka H., Yonetani N., Ohno H., Yamabe H., Fukuhara S.et al. Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets. Genes Chromosomes Cancer. 21:1998;17-29.
28. Buchonnet G., Jardin F., Jean N., Bertrand P., Parmentier F., Tison S.et al. Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease? Leukemia. 16:2002;1852-1856.
29. Price C.G., Tuszynski A., Watt S.M., Murdoch S.J., Lister T.A., Young B.D. Detection of additional JH/BCL2 translocations in follicular lymphoma. Leukemia. 5:1991;548-554.
30. Kneba M., Eick S., Herbst H., Willigeroth S., Pott C., Bolz I.et al. Frequency and structure of t(14;18) major breakpoint regions in non-Hodgkin's lymphomas typed according to the Kiel classification: analysis by direct DNA sequencing. Cancer Res. 51:1991;3243-3250.
31. Yamada M., Wasserman R., Reichard B.A., Shane S., Caton A.J., Rovera G. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. J. Exp. Med. 173:1991;395-407.
32. Gribben J.G., Freedman A.S., Neuberg D., Roy D.C., Blake K.W., Woo S.D.et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 325:1991;1525-1533.
33. Johnson P.W., Price C.G., Smith T., Cotter F.E., Meerabux J., Rohatiner A.Z.et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J. Clin. Oncol. 12:1994;798-805.
34. Sykes P.J., Neoh S.H., Brisco M.J., Hughes E., Condon J., Morley A.A. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 13:1992;444-449.
35. Gilliland G., Perrin S., Blanchard K., Bunn H.F. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A. 87:1990;2725-2729.
36. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 6:1996;986-994.
37. Dölken L., Schüler F., Dölken G. Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes. Biotechniques. 25:1998;1058-1064.
38. Luthra R., McBride J.A., Cabanillas F., Sarris A. Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am. J. Pathol. 153:1998;63-68.
39. Mandigers C.M., Meijerink J.P., Raemaekers J.M., Schattenberg A.V., Mensink E.J. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet. 352:1998;1522-1523.
40. Hirt C., Dölken G. Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant. 25:2000;419-426.
41. Johnson P.W., Swinbank K., MacLennan S., Colomer D., Debuire B., Diss T.et al. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Ann. Oncol. 10:1999;1349-1354.
42. Mandigers C.M., Meijerink J.P., Mensink E.J., Tonnissen E.L., Hebeda K.M., Bogman M.J.et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood. 98:2001;940-944.
43. Galoin S., al Saati T., Schlaifer D., Huynh A., Attal M., Delsol G. Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas. Br. J. Haematol. 94:1996;676-684.
44. Luthra R., McBride J.A., Hai S., Cabanillas F., Pugh W.C. The application of fluorescence-based PCR and PCR-SSCP to monitor the clonal relationship of cells bearing the t(14;18)(q32;q21) in sequential biopsy specimens from patients with follicle center cell lymphoma. Diagn. Mol. Pathol. 6:1997;71-77.
45. Sanchez-Vega B., Vega F., Medeiros L.J., Lee M.S., Luthra R. Quantification of bcl-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. J. Mol. Diagn. 4:2002;223-229.
46. Ladetto M., Donovan J.W., Harig S., Trojan A., Poor C., Schlossnan R.et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol. Blood Marrow Transplant. 6:2000;241-253.
47. Hirt C., Schüler F., Schwenke C., Kiefer T., Herold M., Dölken G. High percentage of molecular remissions in advanced stage follicular lymphoma (FL) patients treated with chemoimmunotherapy in comparison to chemotherapy alone. Blood. 100:2002;362. [abstract 1402].
48. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
49. Vaughan-Hudson B., Vaughan-Hudson G., MacLennan K.A., Anderson L., Linch D.C. Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br. J. Cancer. 69:1994;1088-1093.
50. Mac Manus M.P., Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol. 14:1996;1282-1290.
51. Paryani S.B., Hoppe R.T., Cox R.S., Colby T.V., Kaplan H.S. The role of radiation therapy in the management of stage III follicular lymphomas. J. Clin. Oncol. 2:1984;841-848.
52. Carde P., Burgers J.M., van Glabbeke M., Hayat M., Cosset J.M., Somers R.et al. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial. Radiother. Oncol. 2:1984;301-312.
53. Gribben J.G., Freedman A., Woo S.D., Blake K., Shu R.S., Freeman G.et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 78:1991;3275-3280.
54. Lambrechts A.C., Hupkes P.E., Dorssers L.C., van't Veer M.B. Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma. Blood. 82:1993;2510-2516.
55. Lambrechts A.C., Hupkes P.E., Dorssers L.C., van't Veer M.B. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J. Clin. Oncol. 12:1994;1541-1546.
56. Lopez-Guillermo A., Cabanillas F., McLaughlin P., Smith T., Hagemeister F., Rodriguez M.A.et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 91:1998;2955-2960.
57. Price C.G., Meerabux J., Murtagh S., Cotter F.E., Rohatiner A.Z., Young B.D.et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J. Clin. Oncol. 9:1991;1527-1532.
58. Dölken G., Hirt C. Comparative molecular and quantitative analysis of circulating t(14;18)-positive cells in patients with follicular lymphoma in long-term remission after radiotherapy. Blood. 90:1997;391. [abstract 1741].
59. Ha C.S., Tucker S.L., Lee M.S., McLaughlin P., Cabanillas F., Cox J.D. The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). Int. J. Radiat. Oncol. Biol. Phys. 49:2001;727-732.
60. Horning S.J., Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N. Engl. J. Med. 311:1984;1471-1475.
61. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskins PJ, et al., on behalf of the BNLI. The CRC and UCL Cancer Trialist Centre. The long term impact of a watch and wait policy vs. immediate systemic treatment for asymptomatic advanced stage indolent non-Hodgkin's lymphoma: results of a British National Lymphoma randomised trial. Ann Oncol 2002;13:26 [abstract 76].
62. Kimby E., Bjorkholm M., Gahrton G., Glimelius B., Hagberg H., Johansson B.et al. Chlorambucil/prednisone versus CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann. Oncol. 5(Suppl. 2):1994;67-71.
63. Solal-Celigny P., Lepage E., Brousse N., Tendler C.L., Brice P., Haioun C.et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J. Clin. Oncol. 16:1998;2332-2338.
64. Hagenbeek A., Carde P., Meerwaldt J.H., Somers R., Thomas J., De Bock R.et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J. Clin. Oncol. 16:1998;41-47.
65. Hiddemann W., Griesinger F., Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J. Sci. Am. 4(Suppl. 2):1998;13-18.
66. Fisher R.I., Dana B.W., LeBlanc M., Kjeldsberg C., Forman J.D., Unger J.M.et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J. Clin. Oncol. 18:2000;2010-2016.
67. Rohatiner A., Radford J., Deakin D., Earl H., Love S.B., Price O.et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br. J. Cancer. 85:2001;29-35.
68. Smalley R.V., Weller E., Hawkins M.J., Oken M.M., O'Connell M.J., Haase-Statz S.et al. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen. Leukemia. 15:2001;1118-1122.
69. McLaughlin P., Hagemeister F.B., Romaguera J.E., Sarris A.H., Pate O., Younes A.et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol. 14:1996;1262-1268.
70. Klasa R.J., Meyer R.M., Shustik C., Sawka C.A., Smith A., Guevin R.et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J. Clin. Oncol. 20:2002;4649-4654.
71. Crawley C.R., Foran J.M., Gupta R.K., Rohatiner A.Z., Summers K., Matthews J.et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann. Oncol. 11:2000;861-865.
72. Tsimberidou A.M., McLaughlin P., Younes A., Rodriguez M.A., Hagemeister F.B., Sarris A.et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 100:2002;4351-4357.
73. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A.et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
74. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E.et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:1998;2825-2833.
75. Foran J.M., Gupta R.K., Cunningham D., Popescu R.A., Goldstone A.H., Sweetenham J.W.et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109:2000;81-88.
76. Ghielmini M., Schmitz S.F., Burki K., Pichert G., Betticher D.C., Stupp R.et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 11(Suppl. 1):2000;123-126.
77. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F.et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17:1999;268-276.
78. Hiddemann W, Forstpointner R, Fiedler F, Gramatzki M, Dörken B, Illiger H-J, et al., for the GLSG. The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphoma (MCL) - results of a prospective randomized comparison of the German Low Grade Study (GLSG). Blood 2001;98:844 [abstract 3507].
79. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V.et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 97:2001;101-106.
80. Hainsworth J.D., Burris H.A. III, Morrissey L.H., Litchy S., Scullin D.C. Jr., Bearden J.D. IIIet al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 95:2000;3052-3056.
81. Herold M., Fiedler F., Pasold R., Srock S., Knauf W., Freund M.et al. Efficacy and toxicity of rituximab plus MCP versus MCP alone in advanced indolent NHL - interim results of a clinical phase III study of the East German Study Group Hematology/Oncology (OSHO). Ann. Oncol. 13:2002;145. [abstract 511].
82. Rambaldi A., Lazzari M., Manzoni C., Carlotti E., Arcaini L., Baccarani M.et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 99:2002;856-862.
83. Zinzani PL, on behalf of an Italian Cooperative Study Group on Lymphoma. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL). Blood 2002;100:93 [abstract 344].
84. Ghielmini M., Schmitz S.-F.H., Cogliatti S., Pichert G., Fey M., Betticher D.et al. Prolonged treatment with rituximab significantly improves event free survival and duration of responsein patients with follicular lymphoma: a randomised SAKK trial. Blood. 100:2002;161. [abstract 604].
85. Hainsworth J.D., Litchy S., Burris H.A. III, Scullin D.C. Jr., Corso S.W., Yardley D.A.et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2002;4261-4267.
86. Brugger W., Hirsch J., Repp R., Grünebach F., Schlimok G., Vogel W.et al. Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: a multicenter phase II study. Blood. 100:2002;644. [abstract 2532].
87. Darby A.J., Lanham S.A., Johnson P.W. International multicenter study of variability of detection of the bcl-2/IgH translocation using quantitative PCR. Ann. Oncol. 13:2002;51. [abstract 163].